These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10486365)

  • 1. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure.
    Jeppesen PB; Hartmann B; Hansen BS; Thulesen J; Holst JJ; Mortensen PB
    Gut; 1999 Oct; 45(4):559-63. PubMed ID: 10486365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon.
    Jeppesen PB; Hartmann B; Thulesen J; Hansen BS; Holst JJ; Poulsen SS; Mortensen PB
    Gut; 2000 Sep; 47(3):370-6. PubMed ID: 10940274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.
    Jeppesen PB; Hartmann B; Thulesen J; Graff J; Lohmann J; Hansen BS; Tofteng F; Poulsen SS; Madsen JL; Holst JJ; Mortensen PB
    Gastroenterology; 2001 Mar; 120(4):806-15. PubMed ID: 11231933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY.
    Schmidt PT; Ljung T; Hartmann B; Hare KJ; Holst JJ; Hellström PM
    Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):207-12. PubMed ID: 15674099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic GLP-2 levels do not limit adaptation after distal intestinal resection.
    Topstad D; Martin G; Sigalet D
    J Pediatr Surg; 2001 May; 36(5):750-4. PubMed ID: 11329581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract.
    Gottschalck IB; Jeppesen PB; Holst JJ; Henriksen DB
    Scand J Gastroenterol; 2008 Aug; 43(8):929-37. PubMed ID: 19086164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study.
    Madsen KB; Askov-Hansen C; Naimi RM; Brandt CF; Hartmann B; Holst JJ; Mortensen PB; Jeppesen PB
    Regul Pept; 2013 Jun; 184():30-9. PubMed ID: 23511332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal growth adaptation and glucagon-like peptide 2 in rats with ileal--jejunal transposition or small bowel resection.
    Thulesen J; Hartmann B; Kissow H; Jeppesen PB; Orskov C; Holst JJ; Poulsen SS
    Dig Dis Sci; 2001 Feb; 46(2):379-88. PubMed ID: 11281189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.
    Lugari R; Dell'Anna C; Ugolotti D; Dei Cas A; Barilli AL; Zandomeneghi R; Marani B; Iotti M; Orlandini A; Gnudi A
    Horm Metab Res; 2000 Oct; 32(10):424-8. PubMed ID: 11069208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients.
    Naimi RM; Madsen KB; Askov-Hansen C; Brandt CF; Hartmann B; Holst JJ; Mortensen PB; Jeppesen PB
    Regul Pept; 2013 Jun; 184():47-53. PubMed ID: 23501043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon.
    Haderslev KV; Jeppesen PB; Hartmann B; Thulesen J; Sorensen HA; Graff J; Hansen BS; Tofteng F; Poulsen SS; Madsen JL; Holst JJ; Staun M; Mortensen PB
    Scand J Gastroenterol; 2002 Apr; 37(4):392-8. PubMed ID: 11989828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats.
    Washizawa N; Gu LH; Gu L; Openo KP; Jones DP; Ziegler TR
    JPEN J Parenter Enteral Nutr; 2004; 28(6):399-409. PubMed ID: 15568286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum.
    Dumoulin V; Dakka T; Plaisancie P; Chayvialle JA; Cuber JC
    Endocrinology; 1995 Nov; 136(11):5182-8. PubMed ID: 7588257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans.
    Xiao Q; Boushey RP; Drucker DJ; Brubaker PL
    Gastroenterology; 1999 Jul; 117(1):99-105. PubMed ID: 10381915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of glucagon-like peptide-2 deficiency in neonatal short-bowel syndrome using neonatal piglets.
    Hua Z; Turner JM; Sigalet DL; Wizzard PR; Nation PN; Mager DR; Ball RO; Pencharz PB; Wales PW
    Pediatr Res; 2013 Jun; 73(6):742-9. PubMed ID: 23481550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the 'colonic brake' to gastric emptying.
    Nightingale JM; Kamm MA; van der Sijp JR; Ghatei MA; Bloom SR; Lennard-Jones JE
    Gut; 1996 Aug; 39(2):267-72. PubMed ID: 8977342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.
    Martin GR; Wallace LE; Hartmann B; Holst JJ; Demchyshyn L; Toney K; Sigalet DL
    Am J Physiol Gastrointest Liver Physiol; 2005 Mar; 288(3):G431-8. PubMed ID: 15388486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-2 induces a specific pattern of adaptation in remnant jejunum.
    Sigalet DL; Bawazir O; Martin GR; Wallace LE; Zaharko G; Miller A; Zubaidi A
    Dig Dis Sci; 2006 Sep; 51(9):1557-66. PubMed ID: 16927140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive increase in peptide YY and enteroglucagon after proctocolectomy and pelvic ileal reservoir construction.
    Armstrong DN; Ballantyne GH; Adrian TE; Bilchik AJ; McMillen MA; Modlin IM
    Dis Colon Rectum; 1991 Feb; 34(2):119-25. PubMed ID: 1993408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
    Jeppesen PB; Sanguinetti EL; Buchman A; Howard L; Scolapio JS; Ziegler TR; Gregory J; Tappenden KA; Holst J; Mortensen PB
    Gut; 2005 Sep; 54(9):1224-31. PubMed ID: 16099790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.